Lapaquistat acetate (Synonyms: TAK-475) |
Catalog No.GC38807 |
L'acétate de lapaquistat (TAK-475) est un inhibiteur de la squalène synthase, bloquant la conversion du farnésyl diphosphate (FPP) en squalène dans la voie de biosynthèse du cholestérol .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 189060-13-7
Sample solution is provided at 25 µL, 10mM.
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene[1]. Lapaquistat acetate (TAK-475) is originally intended use to Mevalonate Kinase Deficiency (MKD), it is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage[2].
[1]. Stein EA, et al. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. [2]. Marcuzzi A, et al. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice. Curr Med Chem. 2018;25(24):2783-2796.
Average Rating: 5
(Based on Reviews and 19 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *